← Leaderboards
Gerard Anthony Lutty
Yeshiva University
$14,318,233
Attributed
$14,318,233
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $960.9K · FY2005–24$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$14,318,233 · 9
By mechanism
R01$12,708,668 · 4
P60$647,016 · 1
R03$490,500 · 1
P30$472,049 · 3
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Vascular Endothelial Growth Factors”
- Keri Hammel · The Emmes Company, Llc$41,089,609
- Michael Simons · Yale University$37,207,792
- Norman Wolmark · Nsabp Foundation, Inc.$27,593,122
- Shahin Rafii · Weill Medical College Of Cornell Univ$24,406,332
- Rakesh K. Jain · Massachusetts General Hospital$23,479,897
- Aleksander S. Popel · Johns Hopkins University$19,039,579
Research focus
Vascular Endothelial Growth FactorsAngiogenesisRetinaBlood VesselsEndothelial CellsIn VitroLabelPreventCellsRetinopathy Of PrematurityCytokineRetinalAngiogenesis InhibitorsFetalVasculogenesisStagingNanoparticleTubeCell TypeIn VivoImmunohistochemistryOxygenExudative Age-Related Macular DegenerationFunctional Disorder
Grant awards (47)
Animal Models Module$81,320
P30 · FY2024 · EY · contact PI
Animal Models Module$81,320
P30 · FY2023 · EY · contact PI
Animal Models Module$81,320
P30 · FY2022 · EY · contact PI
Animal Models Module$81,320
P30 · FY2021 · EY · contact PI
Animal Models Module$81,320
P30 · FY2020 · EY · contact PI
Inflammatory cells of choroid: a therapeutic target in AMD.$513,062
R01 · FY2019 · EY · contact PI
Animal Models Module$65,449
P30 · FY2019 · EY · contact PI
Inflammatory cells of choroid: a therapeutic target in AMD.$512,931
R01 · FY2018 · EY · contact PI
Inflammatory cells of choroid: a therapeutic target in AMD.$509,566
R01 · FY2017 · EY · contact PI
Birth and Death of Choriocapillaris.$456,200
R01 · FY2016 · EY · contact PI
Birth and Death of Choriocapillaris.$466,524
R01 · FY2015 · EY · contact PI
Vasculogenesis and hyperoxia in the developing retina.$463,016
R01 · FY2014 · EY · contact PI
Birth and Death of Choriocapillaris.$455,094
R01 · FY2014 · EY · contact PI
Birth and Death of Choriocapillaris.$451,781
R01 · FY2013 · EY · contact PI
Vasculogenesis and hyperoxia in the developing retina.$448,844
R01 · FY2013 · EY · contact PI
Birth and Death of Choriocapillaris.$488,398
R01 · FY2012 · EY · contact PI
Vasculogenesis and hyperoxia in the developing retina.$472,466
R01 · FY2012 · EY · contact PI
Vasculogenesis and hyperoxia in the developing retina.$483,269
R01 · FY2011 · EY · contact PI
Potential target molecules for ischemic retinopathies$350,698
R01 · FY2011 · EY · contact PI
Birth and Death of Choriocapillaris.$354,716
R01 · FY2010 · EY · contact PI
Vasculogenesis and hyperoxia in the developing retina.$315,303
R01 · FY2010 · EY · contact PI
Birth and Death of Choriocapillaris.$358,299
R01 · FY2009 · EY · contact PI
Vasculogenesis and hyperoxia in the developing retina.$318,488
R01 · FY2009 · EY · contact PI
Birth and Death of Choriocapillaris.$351,134
R01 · FY2008 · EY · contact PI
Vasculogenesis and hyperoxia in the developing retina.$312,118
R01 · FY2008 · EY · contact PI
Birth and Death of Choriocapillaris.$354,938
R01 · FY2007 · EY · contact PI
Vasculogenesis and hyperoxia in the developing retina.$318,488
R01 · FY2007 · EY · contact PI
Birth and Death of Choriocapillaris.$364,672
R01 · FY2006 · EY · contact PI
Vasculogenesis and hyperoxia in the developing retina.$327,000
R01 · FY2006 · EY · contact PI
Vaso-occlusive processes in sickle cell retinopathy$253,641
R01 · FY2006 · HL · contact PI
Vaso-occlusive processes in sickle cell retinopathy$259,744
R01 · FY2005 · HL
THE ROLE OF ADENOSINE IN RETINAL VASCULOGENESIS$363,876
R01 · FY2004 · EY
Vaso-occlusive processes in sickle cell retinopathy$259,744
R01 · FY2004 · HL
THE ROLE OF ADENOSINE IN RETINAL VASCULOGENESIS$363,876
R01 · FY2003 · EY
Vaso-occlusive processes in sickle cell retinopathy$277,398
R01 · FY2003 · HL
Nanoparticle delivery of antiangiogenic genes$163,500
R03 · FY2003 · EY
THE ROLE OF ADENOSINE IN RETINAL VASCULOGENESIS$363,876
R01 · FY2002 · EY
MECHANISM OF SICKLE CELL RETENTION IN THE RETINAL VASCULATURE$175,153
P60 · FY2002 · HL
MECHANISM OF SICKLE CELL RETENTION IN THE RETINAL VASCULATURE$175,153
P60 · FY2002 · HL
Nanoparticle delivery of antiangiogenic genes$163,500
R03 · FY2002 · EY
THE ROLE OF ADENOSINE IN RETINAL VASCULOGENESIS$360,066
R01 · FY2001 · EY
VASO-OCCLUSIVE PROCESSES IN SICKLE CELL RETINOPATHY$196,806
R01 · FY2001 · HL
MECHANISM OF SICKLE CELL RETENTION IN THE RETINAL VASCULATURE$175,153
P60 · FY2001 · HL
Nanoparticle delivery of antiangiogenic genes$163,500
R03 · FY2001 · EY
THE ROLE OF ADENOSINE IN RETINAL VASCULOGENESIS$360,968
R01 · FY2000 · EY
VASO-OCCLUSIVE PROCESSES IN SICKLE CELL RETINOPATHY$201,668
R01 · FY2000 · HL
MECHANISM OF SICKLE CELL RETENTION IN THE RETINAL VASCULATURE$121,557
P60 · FY2000 · HL